Citigroup
PGNX

Citigroup’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Citigroup’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-11,200
Closed -$57K – 7895
2019
Q4 		$57K Hold
11,200
– – ﹤0.01% 6207
2019
Q3 		$57K Sell
11,200
-5,100
-31% -$25.4K ﹤0.01% 6050
2019
Q2 		$101K Buy
16,300
+2,700
+20% +$13K ﹤0.01% 5867
2019
Q1 		$63K Sell
13,600
-12,200
-47% -$55.2K ﹤0.01% 6151
2018
Q4 		$108K Sell
25,800
-7,800
-23% -$39.7K ﹤0.01% 5592
2018
Q3 		$211K Sell
33,600
-15,900
-32% -$122K ﹤0.01% 5200
2018
Q2 		$398K Buy
49,500
+22,900
+86% +$175K ﹤0.01% 4348
2018
Q1 		$198K Buy
26,600
+12,500
+89% +$83.1K ﹤0.01% 4978
2017
Q4 		$84K Sell
14,100
-1,000
-7% -$6.08K ﹤0.01% 5800
2017
Q3 		$111K Buy
15,100
+3,600
+31% +$22.9K ﹤0.01% 5484
2017
Q2 		$78K Sell
11,500
-6,200
-35% -$45.8K ﹤0.01% 5522
2017
Q1 		$167K Buy
17,700
+5,500
+45% +$54.9K ﹤0.01% 4813
2016
Q4 		$105K Buy
12,200
+11,900
+3,967% +$88K ﹤0.01% 5743
2016
Q3 		$2K Buy
+300
New +$1.81K ﹤0.01% 6946

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Citigroup's PGNX Position: Q2 2020 in Review

Citigroup sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 79,324 shares — an estimated $301K sold.

Citigroup first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $2.37M in Q4 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Citigroup reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Citigroup sold 79,324 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $301K.
  • Citigroup first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Citigroup's Progenics Pharmaceuticals Inc position peaked at $2.37M in Q4 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Citigroup's 13F filing for Q2 2020, filed 12 Aug 2020.